Compare Gilead Sciences, Inc. (GILD) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Suncor Energy Inc. — how do they compare? Gilead Sciences, Inc. trades at $134.56 (market cap $163.51B), while Suncor Energy Inc. trades at $60.78 (market cap $70.89B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| GILD | SU | |
|---|---|---|
Market Cap | $163.51B | $70.89B |
Sector | Health | Energy |
52-Week High | $155.80 | $69.73 |
52-Week Low | $108.22 | $38.17 |
Enterprise Value | $178.05B | $79.02B |
Dividend Yield | 2.49% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Suncor Energy (SU) trades at $61.27, up 0.38% on the day, with a bullish technical signal supported by moving averages. The company reported a Q1 2026 earnings miss but beat expectations in prior quarters, maintaining solid profitability with an 11.62% net income margin. Recent news highlights operational improvements and strong cash flows, while analyst consensus is strongly bullish with 74% buy ratings.
Outlook remains positive due to disciplined capital allocation and record production, though risks include oil price volatility and operational incidents. The stock's valuation appears reasonable with a P/E of 16.37, offering potential for growth if energy demand sustains. Investors should weigh macroeconomic headwinds against the company's robust fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
